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grouped by gender and age. The study was conducted
from the societal perspective using Year 1996–1999
prices, adjusted to year 2000 by CPI. Life expectancies
were adjusted for QOL using the Index of Well-Being.
Probabilities and prices were collected from the litera-
ture, the SEER program, National Vital Statistics, and
BLS. The model considered H. pylori reinfection and gas-
tric carcinogenesis risk over time. One-way sensitivity
analyses were conducted on critical or uncertain parame-
ters and threshold analyses on pivotal parameters. RE-
SULTS: The incremental cost-effectiveness ratio (ICE) for
pooled patients (both genders) decreases with age from
$3,612 per quality adjusted life year (QALY) saved at age
40–44 to the minimum of $200 (dominant) per QALY
saved at age 65–70. After age 70, the ICE increases with
age. Females have higher ICEs than males in every age
subgroup. The ICE was sensitive to discount rate, relative
risk of gastric cancer (GC) in H. pylori infected patients,
cost of treating GC, and cost of empiric antisecretory
therapy, but not to the reinfection rate or infection rate
of H. pylori, the change of the utility rate of GC and the
one-year utility of dyspepsia patient under empiric anti-
secretory therapy. CONCLUSIONS: Taking $50,000/
QALY as the societal ICE threshold, H. pylori screening
and eradication is cost-effective for both genders at any
age group, especially for male patients at older ages. Bet-
ter estimates are needed for certain key parameters such
as the relative risk reduction of GC with H. pylori eradi-
cation.
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OBJECTIVES: Meperidine/midazolam (M/M) and pro-
pofol (P) are clinically effective alternatives for sedation
during endoscopic procedures. Propofol has a higher ac-
quisition cost, but may be associated with cost savings
due to shorter duration of post-procedure care. The ob-
jective of this project was to compare the costs associated
with complex upper endoscopic procedures (ERCP/EUS)
in subjects who received either M/M or propofol.
METHODS: Subjects scheduled for ERCP/EUS were ran-
domized to receive M/M or P during the procedure. A
blinded observer assessed time to recovery using a stan-
dard 10-point postanesthesia recovery score (PARS) ev-
ery 15 minutes. Once a PARS score of 10 was reached,
the study terminated and the subject was discharged from
the recovery ward. The cost of drug (source: Redbook),
an anesthetist for the propofol group (source: Bureau of
Labor Statistics), recovery room personnel costs (source:
Bureau of Labor Statistics), and overhead costs were
compared from the institutional perspective. A sensitivity
analysis was performed by assuming generic drug, a
nurse anesthetist, and licensed practical nurse (LPN) care
in the recovery ward. RESULTS: 33 and 31 subjects were
randomized to receive M/M and P, respectively. There
were no significant differences detected between the
groups in age, gender, case severity, or procedure dura-
tion. P group subjects had a significantly shorter post-
procedure recovery time (19 minutes) compared with
M/M group subjects (71 minutes, p  0.001). Subjects in
the M/M group cost an average of $65 per case, while P
group subjects cost an average of $144 per case (p 
0.001). The sensitivity analysis resulted in an average
cost of $77 per case in the P group and $34 in the M/M
group (p  0.001). CONCLUSIONS: Subjects in the P
group had a significantly shorter post-procedure recovery
time but this did not result in cost savings compared with
subjects treated with M/M.
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OBJECTIVES: Treatment effects are often evaluated by
comparing groups in terms of the proportion of “re-
sponders”, i.e., patients who achieve some prospectively
defined outcome. In the absence of additional data, it is
assumed that responders in different treatment groups
achieve comparable benefits and therefore that the treat-
ment benefit is fully described by the responder rates.
This study compared the HRQOL changes of responders
in two treatment groups. METHODS: In two identical
randomized, double-blind, placebo-controlled studies
(S3BA3001; S3BA3002) in women evaluating 12 weeks
of treatment with alosetron 1mg BID, patients completed
the Irritable Bowel Syndrome Quality of Life Question-
naire (IBSQOL) at baseline and at the final treatment
visit. A patient was classified as a responder if she
achieved adequate relief of IBS pain and discomfort on at
least 2 of 4 weeks for all 3 months. This post-hoc analysis
compared responders from the two treatment groups in
terms of IBSQOL change from baseline scores at the final
visit using analysis of covariance. The analysis focused on
patients with diarrhea-predominant IBS. RESULTS: Our
analyses included 154 patients (96 alosetron and 58 pla-
cebo) in S3BA3001 and 172 (110 alosetron and 62 pla-
cebo) in S3BA3002. Compared with placebo responders,
those in the alosetron group had significantly higher (p 
.05) scores on 5 of 9 IBSQOL scales (sleep; energy; physi-
cal functioning, food and role-physical) in S3BA3001 and
on 4 scales (sleep, energy, food and social functioning) in
S3BA3002. CONCLUSIONS: Adequate relief responders
in the alosetron group experienced significantly greater
HRQOL improvements relative to placebo group re-
sponders. This suggests that treatment benefits may be
underestimated when described only in terms of the addi-
tional proportion of responders. Reporting HRQOL dif-
